Journal
CANCER JOURNAL
Volume 18, Issue 2, Pages 148-152Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/PPO.0b013e31824bd256
Keywords
Uveal melanoma; GNAQ; GNA11; BAP1
Categories
Funding
- National Cancer Institute [P50CA093459]
- National Institutes of Health [K12CA088084]
- GlaxoSmithKline
- Bristol Myers Squibb
Ask authors/readers for more resources
Uveal melanoma is the most common primary intraocular cancer in adults. Nearly half of primary uveal melanoma tumors metastasize, but there are currently no effective therapies for metastatic uveal melanoma. The recent discovery of mutations that underlie uveal melanoma metastasis, growth, and survival provide a key to the molecular understanding of this disease. Much work is now underway to leverage this knowledge to develop effective therapies. This review summarizes recently discovered molecular features of uveal melanoma and therapies being explored to capitalize on this knowledge.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available